Homozygous FCGR3A-V/V158 individuals were more likely to experience complete remission from immune thrombocytopenia following medication, but conversely remission rates after splenectomy were higher in homozygous FCGR3A-F/F158 or heterozygous individuals (70). This evidence concerns the gene FCGR3A and autoimmune thrombocytopenic purpura.